



Issues for Product Authorization: The Industry Experience

Jack Poppleton

Director, Head Global Regulatory Affairs

Arch Timber protection





Content

- Historical Background
- Suppliers and formulators - partnership or competition?
- Technical issues and opportunities
- Procedural issues
- Costs & Timing
- Summary

Historical Background

- **15 years and counting**
 - BPD programme started in 2000
 - Anticipated 10 year programme
 - BPR now looking to a programme to 2025
- **Major changes**
 - Over this timeline significant fundamental changes have occurred
 - Technical and Procedural changes
 - Complexity unravelling
- **How does the formulator keep pace with the change and remain competitive?**

Suppliers and formulators - partnership or competition?

- **BPD/BPR is a two phase system**
 - Phase 1 - Active substances
 - Phase 2 - Biocidal products
- **Active substances**
 - Prime objective to gain entry onto the Union List
 - One single use to be demonstrated for listing
 - May be based on "dummy product"
 - Some cases where no supplier would support the AI
- **Biocidal Products**
 - Authorisation for every product
 - Authorisation primarily in every country in the Union
 - Limitations to Union Authorisation
 - Link to active substance (Letter of Access)
 - Product Family approach

Suppliers and formulators - partnership or competition?

- The Inclusion decision
 - Sets an initial envelope for authorisation of Products
- By no means an exhaustive evaluation of the active AND its use in products
 - Certainly not an evaluation of combinations of actives
- Likely to include a set of restrictions which could significantly impact your existing market
 - E.g. Professional or non-professional use
 - May include the need for significant mitigation measures

Suppliers and formulators - partnership or competition?

- How useful is the Inclusion decision?
- Data gaps
 - In the rush to meet the timetable for completion of the active substance review programme, many decisions are left to Product Authorisation phase
 - Who will provide the data?
 - Who will own the data?
 - How will the data be presented and evaluated?
 - If there are multiple suppliers, does every supplier have a full data set
 - Do they have access to data not yet used that could be useful?
- How useful is the Article 95 List?

Suppliers and formulators - partnership or competition?

- The AI supporters intent may not fit with your requirements
 - Is their supported use for Inclusion the same as your needs?
 - How did the evaluation process compare with the original intent?
 - Even where data has been examined under national schemes previously, the new interpretation is likely to much more conservative and therefore restrictive to your uses
- **Decision Time**
 - Do you partner with an AI supplier or simply buy on the market?

Technical issues and opportunities

- Long evaluation time has had significant implications
- Adaptation to technical progress has changed the guidance documents
- and Regulators interpretation of the guidance
- This has also potentially changed interpretation of existing data, exposures etc. or
- Set new data requirements at product authorisation phase for both the product and the active substance
- Increasing importance of hazard profiles / classification

Technical issues and opportunities

- Products are the result of a significant product development programme
- Typically 5 years of development PLUS registration time
 - Efficacy and use pattern
 - Product Stability
 - Specific tox / ecotox data
- Many formulated product are a combination of actives and uncertainty on any active is multiplied at the product phase.
 - The AI supplier will have only considered their substance, not the combinations
 - $PEC/PNEC$ for product = Summation of $PEC/PNEC$ of all substances in the product

Procedural issues

- New technology
 - Increasing drive towards electronic systems for applications and data submission
 - How many SME's will have the ability to use such systems?
- IUCLID
- SPC Editor
- R4BP3
 - Many teething problems.
 - Caused numerous issues.
 - Prevented applications in some cases.
 - IT updates issued without sufficient testing.
 - Fix a problem but create others.
 - Compatibility/upload issues.
 - MS have similar problems.

Procedural issues

- Mutual recognition
 - One primary application to the Reference Member State
 - MR in other states
- Experience with RefMS and MR
 - Not a simple system
 - Very common for MS to reject MR
 - In some cases even data evaluated at AI stage is re-evaluated at MR stage
 - Experience and Legal developments are improving this
- However.....
- Are Reference MS now being much more conservative in their approach to primary authorisation so as to avoid challenges at the MR stage?

Procedural issues

- New data
 - Under the AI evaluation programme, new data has not been considered
 - Where data has been developed either to answer existing requirements or to further elaborate on the substance or product profiles, how is it to be submitted?
 - What will be considered relevant ?
 - Will there be an open approach to accepting new data or will the pressure on time reject such new approaches?
 - How will the Assessment report for the Active Substance be updated
 - What are the timelines for all of this

Costs & Timing

- Companies have to face the commercial reality
 - Suppliers have the costs of active substance investment and commercial operability
 - Formulators have to face the supplier cost, the development costs of their products, and the market acceptability.
 - Authorisation costs are very significant - affordable?
- The charging regimes are onerous and differ State to State and according to the type of application
- Timing is not always as given in the Regulation, issues may arise that change the timescales

Costs & Timing

- Products are the result of a significant product development programme
 - Typically 5 years of development PLUS registration time
- AI Listings are for a maximum of 10 years
 - Review starts 550 days before actual renewal date
- If experience of the BPD is any pointer to future developments, then what confidence can formulators have to undergo a development programme which may be undermined by the renewal phase?

Some experiences

Some thoughts on experiences-

- Critical to Understand the IT tools
 - When they don't work, how do you work with your MS?
- Mutual recognition - will it ever work properly?
 - Apparent lack of trust between some MS
 - Too many differences of opinion.
 - Process takes far too long
 - Costs in some MS are unacceptable
 - paying for re-evaluation?

Some experiences

Some thoughts on experiences-

- Communication with MS.
 - Some are very good.
 - Some do not respond.
 - One way communication in some cases.
 - Applicant should be kept up to date but this is not always the case.
- Timelines not always observed.
 - Can take much longer than those set in BPD or the Regulation.

So what to do?

- Plan your application well in advance.
 - The whole process is very complicated.
- Read any guidance documents carefully
- Then read them again!
 - Some of it is still not clear and open to different interpretations even between Member States.
- Choose your member state carefully.
 - Is your application for a single MS or multiple MS?
 - If the latter, then which will provide the greatest assurance of Mutual recognition

So what to do?

- Understand exactly how your product will be used and ensure you cover what you want.
 - Make sure that you explain both the product and its uses clearly in your application
 - The regulator may not know your uses well. He will know your product even less.
- Understand the active reviews.
 - Ensure you fit within active substance approvals or that you cover data gaps/uses etc. in full.
 - Consider your relationship with the AI supplier
 - How much help can they give?
 - How do you protect your Intellectual Property?
 - Insist upon Confidentiality Agreements

So what to do?

- Explain your product and its use clearly.
- Run risk assessments early to identify areas of concern.
 - Understand your risk assessment and models.
 - Do they really work?
 - Do the answers make sense?
- Would you benefit from a Product Family approach?
 - More complex
 - More expensive
 - Potentially more flexible.
- Anticipate questions.
 - Avoids delays and potential costs.

Talk to the regulator before submission if necessary.

Summary

- The route to product authorisation is NOT paved with gold
- There are many rocks strewn across the path
- Critical to form good relationships:
 - Supplier to formulator
 - Formulator to regulator
 - Formulator to customer
- Critical to understand the process and be able to work within the limitations set
- Some companies will not survive the onslaught